

Nadroparin calcium

Calcinosis cutis: case report

A 28-year-old woman developed calcinosis cutis during treatment with nadroparin calcium for antithrombotic prophylaxis.

The woman had undergone a liver transplant 3 months earlier and was receiving nadroparin calcium by subcutaneous injection [*dosage and duration of treatment to reaction onset not stated*]. She was acutely admitted to hospital due to sudden onset of high fever, chills and abdominal pain. On admission, she had low blood pressure and severe tachycardia. There were also multiple non-painful lesions present on her upper legs. These lesions were firm with an erythematous yellow border and measured up to 2.5cm in size. Her laboratory results were as follows: corrected calcium 2.39 mmol/L, phosphate 1.15 mmol/L, creatinine 123 μ mol/L, C reactive protein 61 mg/L and leukocytes $0.9 \times 10^9/L$.

The woman was treated with broad spectrum antibiotics and volume replacement. Her condition stabilised over 12 hours and she gradually recovered. Her skin lesions did not change. The histopathology revealed a dermal deposition of calcium salts which caused skin inflammation [*outcome not stated*].

Author comment: "*The diagnosis is calcinosis cutis due to nadroparin injections*".

Olde Bekkink M, et al. A patient with cutaneous lesions after liver transplantation. Netherlands Journal of Medicine 71: 33&36, No. 1, Jan 2013 - Netherlands

803093652